- Home
- SOPH vs SLDB Comparison
SOPH vs SLDB Comparison
Compare SOPH & SLDB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SOPH
- SLDB
- Stock Information
- Founded
- SOPH 2011
- SLDB 2013
- Country
- SOPH Switzerland
- SLDB United States
- Employees
- SOPH N/A
- SLDB N/A
- Industry
- SOPH Biotechnology: Biological Products (No Diagnostic Substances)
- SLDB Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SOPH Health Care
- SLDB Health Care
- Exchange
- SOPH Nasdaq
- SLDB Nasdaq
- Market Cap
- SOPH 206.6M
- SLDB 234.8M
- IPO Year
- SOPH 2021
- SLDB 2018
- Fundamental
- Price
- SOPH $2.93
- SLDB $2.76
- Analyst Decision
- SOPH Strong Buy
- SLDB Strong Buy
- Analyst Count
- SOPH 2
- SLDB 9
- Target Price
- SOPH $6.50
- SLDB $15.67
- AVG Volume (30 Days)
- SOPH 26.9K
- SLDB 1.6M
- Earning Date
- SOPH 05-06-2025
- SLDB 05-19-2025
- Dividend Yield
- SOPH N/A
- SLDB N/A
- EPS Growth
- SOPH N/A
- SLDB N/A
- EPS
- SOPH N/A
- SLDB N/A
- Revenue
- SOPH $67,173,000.00
- SLDB N/A
- Revenue This Year
- SOPH $14.86
- SLDB N/A
- Revenue Next Year
- SOPH $22.76
- SLDB $569.02
- P/E Ratio
- SOPH N/A
- SLDB N/A
- Revenue Growth
- SOPH 4.66
- SLDB N/A
- 52 Week Low
- SOPH $2.58
- SLDB $2.45
- 52 Week High
- SOPH $6.28
- SLDB $10.99
- Technical
- Relative Strength Index (RSI)
- SOPH 44.97
- SLDB 41.52
- Support Level
- SOPH $2.90
- SLDB $2.52
- Resistance Level
- SOPH $3.33
- SLDB $4.35
- Average True Range (ATR)
- SOPH 0.21
- SLDB 0.45
- MACD
- SOPH 0.00
- SLDB -0.02
- Stochastic Oscillator
- SOPH 21.78
- SLDB 13.11
About SOPH SOPHiA GENETICS SA
Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.
About SLDB Solid Biosciences Inc.
Solid Biosciences Inc is a life science company. It is engaged in the manufacturing of specialty and generic drugs. The company is involved in curing Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age. The company's pipeline products are the SB-001 and solid suit. The Company's singular focus is on developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases. The company has categorized its programs into corrective therapies, disease-modifying therapies, and assistive devices.